Mergers & Acquisitions (Healthcare)
References of the ZETRA team and our international network
icotec raises $30m in growth financing from MVM Partners
ALTSTAETTEN, Switzerland, and Connecticut, United States, January 24, 2024 /PRNewswire/ — icotec ag, the leading company in the field of innovative spinal tumor implants is pleased to announce a significant milestone in its growth journey by establishing a strategic partnership with MVM Partners (“MVM”), a global healthcare venture capital firm. icotec is commercializing groundbreaking BlackArmor® Carbon/PEEK products that may offer significant clinical advantages over traditional metal implants in the context of spine oncology, making the full potential of the treatment possibilities available for patients along their journey.
Since receiving FDA clearance in 2019, many designated US cancer centers have adopted icotec’s BlackArmor® products. This investment will enable icotec to continue its impressive growth and strengthen its research and development capabilities to expand the portfolio into the underserved indications of spinal infection and osteoporosis.
“We are thrilled to partner with MVM, whose deep understanding of the healthcare landscape aligns seamlessly with our vision for the future. This partnership marks a pivotal moment for icotec, supporting us to advance our mission of improving patient outcomes by offering a convincing alternative to the 100-year-old material technology of metal implants.” said Roger Stadler, Group CEO of icotec ag.
MVM has a strong track record of supporting and partnering with innovative healthcare companies and recognizes the potential of icotec’s technology to transform patient care. The partnership represents a vote of confidence in icotec’s leadership, products, and the overall trajectory of the company.
“We are excited to support icotec in its mission to revolutionize the spinal implant industry,” commented Thomas Casdagli, Partner at MVM. “icotec’s BlackArmor® Carbon/PEEK implants represent a huge step forward in the treatment of complex spine disease. For the first time clinicians have the choice to be able to accurately visualize and treat patients after surgery without the artifacts and limitations of traditional metal implants. We see this as a big step forward for patient care. We look forward to working closely with the icotec team to drive continued success and growth.”
WISTAMA Finanz- und Beteiligungs AG, the family office of the Stadler family that founded icotec, remains fully invested as majority shareholder and committed to the long-term development of icotec.
About icotec ag
icotec is the leading company for the treatment of spinal tumors with a new generation of high-tech implants. With its BlackArmor® Carbon/PEEK implants, icotec combines cutting-edge technologies and industry expertise to deliver innovative and reliable solutions for spine surgeons and their patients and is dedicated to advancing the field of spinal implantation. With a track record of clinical success and a commitment to continuous innovation, icotec is poised to shape the future of spinal surgery. The comprehensive product portfolio has received FDA approval and is supported by numerous Key Opinion Leaders and Cancer Therapy Centers worldwide. More information can be found at www.icotec-medical.com.
About MVM Partners
MVM has invested in high-growth healthcare businesses since 1997. With teams in Boston and London, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at www.mvm.com.
ZETRA AG acted as exclusive M&A advisor to icotec.
Biosynth to Offer Complex Chemistry Solutions at Greater Scales Following Acquisition of VIO Chemicals
Staad, December 19 2023 – Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired VIO Chemicals, a Zurich-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners.
The acquisition will expand Biosynth’s ability to secure its customers’ supply chains by bringing greater flexibility in scales for complex chemical manufacturing, with expertise across carbohydrates, nucleosides, intermediates, and specialty excipients, among others.
CEO and President of Biosynth, Urs Spitz, was pleased to welcome Biosynth’s long-standing collaborator. “VIO Chemicals has a long standing relationship with Biosynth and is an excellent addition to our flagship Complex Chemicals division. We know that our customers want to stay working with us as their needs develop, so being able to offer flexibility and scope for greater scales of production, into the many metric tons, is an important part of that.”
“Biosynth’s passion for chemistry has always been something that we have shared,” commented VIO Chemicals CEO and Founder, Dimitris Kalias. “We are both driven by both science and our customers’ needs, and I am excited for VIO to be part of the research, development, and manufacturing services that support our shared customers across a wide range of scales.”
About Biosynth
Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides, and Key Biologics, all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.
About VIO Chemicals
VIO Chemicals is specialized in the custom design and production of specialty chemicals, intermediates and Active Pharmaceutical Ingredients (APIs). The story of VIO Chemicals began with a passion for chemistry as a start-up company in the high-end business environment of Zurich, Switzerland in 2001. It has since grown to a global provider with a portfolio of 2,500 products delivered to the world's leading companies all over the Americas, over 20 European countries and Asia. Today, VIO Chemicals is the exclusive and trusted partner for customers and suppliers in the chemical and pharmaceutical industry worldwide.
ZETRA AG acted as exclusive M&A advisor to the seller.
Die Kliniken Valens und die Zürcher RehaZentren haben fusioniert. Damit bündeln die beiden Klinikgruppen ihre gemeinsamen Stärken in Qualität, Forschung und Entwicklung, aber auch als Arbeitgeber und Nr. 1 im Markt
Gemeinsam verfügen die Zürcher RehaZentren und die Kliniken Valens über acht stationäre und fünf ambulante Standorte, acht Fachbereiche und über 175 Jahre Erfahrung.
Die beiden Unternehmen können dank der Synergien zukünftig mehr Ressourcen in Innovationen stecken. Sie wollen als Trendsetter folgendes erreichen: (1) die Weiterentwicklung der Rehabilitation vorantreiben, (2) der integrierten und wohnortnahen Rehabilitation zum Durchbruch verhelfen und (3) mit den technischen und digitalen Möglichkeiten die Rehabilitation zu den Patienten nach Hause bringen.
Die nun grosse Gruppe kann darüber hinaus die Wünsche der Mitarbeitenden nach flexibleren Arbeitszeitmodellen noch besser erfüllen.
Die Standorte der beiden Klinikgruppen ergänzen sich ideal und bilden die Basis für eine zukunftsfähige Strategie im wachsenden und immer wichtiger werdenden Rehabilitationsmarkt.
In der fusionierten Gruppe erhalten allein in der Region Zürich jedes Jahr insgesamt 4'800 Patientinnen und Patienten eine ganzheitliche Rehabilitation.
ZETRA AG hat sowohl die Kliniken Valens als auch die Zürcher RehaZentren als exklusive M&A-Beraterin bei dieser für den Schweizer Rehabilitationsmarkt wegweisenden Transaktion begleitet.
Nordic Consulting Partners completes acquisition of Healthtech Consultants
Toronto, January 31, 2019
The sale of Healthtech Consultants to Nordic Consulting Partners was the result of a successful international sale process. This founder-led succession driven transaction included a targeted canvass of strategic acquirers in Canada and the United States. The acquisition, Nordic’s first outside the US, was highly strategic as it provides them with a strong partner in the Canadian market that has deep and long-standing customer relationships in the healthcare community.
About Healthtech Consultants
Founded in 1983, Healthtech Consultants is the leading Canadian provider of IT solutions for the health sector. Healthtech is recognized as a top 10 Global Healthcare IT consulting firm by KLAS Research.
Global M&A Partners acted as financial advisor to Healthtech and assisted with the negotiation and structuring of the transaction
Colosseum Dental Group completes the acquisition of Oral Hammaslaakarit Plc
Espoo, November 01, 2017
Colosseum Dental Group, a Switzerland-based provider for dentistry services, and a portfolio of Jacobs Holding AG, a Switzerland-based investment firm, has agreed to acquire Oral Hammaslaakarit Plc, a Finland-based provider of dental health care services through a chain of dental clinics, from CapMan Plc, a listed Finland-based private equity firm. Oral is a private dentistry chain with 63 clinics and sales close to EUR 100m.
The transaction will help Oral in its further growth and development, thereby enforcing its ongoing initiatives. The transaction will enable Colosseum to develop a Pan-European dentistry platform. Post-acquisition, Mr. Martin Forss, CEO of Oral, and his team will continue to run the business.
Global M&A Partners acted as financial advisor to CapMan and other shareholders of Oral Hammaslaakarit.
ACQUISITION of a high-end medical treatment services provider
Global M&A Partners Advises in the Sale of Preclinical ADME-Toxicology Services Provider Cyprotex PLC
Press Release from January 10, 2017
Global M&A Partners is pleased to announce the sale of Cyprotex PLC (AIM:CRX) to Evotec AG (XTRA:EVT). Global M&A Partners served as the exclusive financial advisor to Cyprotex in the transaction. Evotec acquired 100 percent of the outstanding shares of Cyprotex in an all-cash transaction valued at £55.7 million effective December 15, 2016.
With the acquisition, Evotec will strengthen its high-end drug discovery platform and capabilities with access to the market’s most industrialized ADME-Tox platform and proven expertise in in vitro ADME screening, mechanistic and high-content toxicology screening, and predictive modeling.
About Cyprotex
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1,500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry, and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010, and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics, and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target-based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology, and high content toxicology screening services, including its proprietary CellCiphr(R) toxicity prediction technology, bioscience services, and predictive modeling solutions including Cloe(R) PK, chemPK(TM), chemTarget, chemTox, and DDI-Fusion and a range of skin, ocular, and endocrine disruption services. For more information, please visit www.cyprotex.com.
About Evotec
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Evotec operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target to clinic to meet the industry’s need for innovation and efficiency in drug discovery. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies, as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical, and discovery stages. For additional information please go to www.evotec.com.
Global M&A Partners Announces the Sale of Riverside Pain Physicians
Press Release from June 24, 2016
Global M&A Partners is pleased to announce the sale of Riverside Pain Physicians (Riverside), and certain affiliates, to Surgery Partners (NasdaqGS: SGRY). Global M&A served as the exclusive financial advisor to Riverside in the transaction. The specific terms of the transaction were not disclosed.
Founded in 2002 and headquartered in Jacksonville, Florida, Riverside is the largest interventional pain practice in Northeast Florida, with 9 pain physicians and 80 support clinicians. The integrated practice specializes in interventional and non-invasive pain management, complemented by a full suite of ancillary services including pharmacy, anesthesia, and laboratory services, as well as durable medical equipment sales. Riverside will become the foundation for Surgery Partner's pain platform in the Southeast United States.
Based in Nashville, Tennessee, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 140 locations across 29 states, including ambulatory surgery centers, surgical hospitals, a diagnostic laboratory, multi-specialty physician practices, and urgent care facilities. H.I.G. Capital is a majority shareholder in the company.
BUY-OUT of a minority shareholder
Akquisition der Rheinburg-Klinik Gruppe durch die Stiftung Kliniken Valens und Walenstadtberg
Walzenhausen/Pfäfers, 19. Dezember 2014
Die Stiftung Kliniken Valens und Walenstadtberg, Trägerin der Kliniken Valens, übernimmt mit sofortiger Wirkung die Rheinburg-Klinik Gruppe, Walzenhausen. Mit dieser Übernahme werden die Kliniken Valens mit rund 260 Reha-Betten, Ambulatorien in den Kantonen St. Gallen, Graubünden und Appenzell Ausser-rhoden und über 800 Mitarbeitenden eine der grössten Rehabilitationsinstitutionen der Schweiz.
Das 60-Bettenhaus Rheinburg-Klinik ist ebenso wie die Kliniken Valens spezialisiert auf die Rehabilitation von neurologischen und rheumatologisch / orthopädischen Patienten und passt damit optimal zum Profil der Stiftung. Durch diese Übernahme sind die Kliniken Valens der wichtigste Reha-Leistungserbringer der Ostschweiz und bevorzugter Anbieter für das Fürstentum Liechtenstein.
Der steigende Bedarf an guten Rehabilitationsplätzen, u.a. eine Folge der demographischen Entwicklung, erfordert einen Ausbau hochstehender Rehabilitationsleistungen. Durch die Konzentration von Fachwissen und Erfahrung können die Angebote weiter gestärkt werden. "Mit der Übernahme sind wir optimal aufgestellt, um uns in unserem Kerngebiet, der Ostschweiz, erfolgreich behaupten zu können", betont Christoph Glutz, Präsident des Stiftungsrates.
Mit dem Erwerb der Aktien wird die Rheinburg-Klinik Walzenhausen zur 100-prozentigen Tochter der Stiftung Kliniken Valens und Walenstadtberg. Chefarzt Dr. Martin Rutz und Beat Voegeli, Leiter Betrieb & Services, bleiben in der Rheinburg-Klinik in ihren Funktionen weiterhin tätig, nehmen aber neu Einsitz in die Geschäftsleitung der Kliniken Valens. "Das Zusammengehen mit den Kliniken Valens ist für alle ein echter Glücksfall, haben wir doch ähnliche Stärken, die wir nutzbringend zusammenführen können." ist Chefarzt Dr. Martin Rutz überzeugt.
Der Betrieb der Rheinburg-Klinik wird im bisherigen Rahmen mit den bestehenden Mitarbeitenden weitergeführt. "Mit dieser frühzeitigen Nachfolgeregelung erfüllt sich das oberste Ziel der bisherigen Eigentümer, Verwaltungsratspräsident Erich Walser, Martin Rutz und Beat Voegeli, die langfristige Sicherung des erfolgreichen Konzepts und der vielfältigen Arbeitsplätze im Appenzeller Vorderland", betont Voegeli.
Das ZETRA Team hat die Käuferin bei dieser Transaktion als exklusiver M&A Berater begleitet.
Verkauf der Rehabilitationsklinik kneipp-hof Dussnang an die VAMED
Wien und Dussnang, 14. Juli 2014
Der internationale Gesundheitskonzern VAMED (eine Tochtergesellschaft der deutschen Fresenius Gruppe) baut seine Aktivitäten in der Schweiz weiter aus und erwirbt 100% der Aktien der Schweizer Betriebsgesellschaft kneipp-hof Dussnang AG. Der Credit Suisse Real Estate Fund LivingPlus, ein Immobilienfonds der Credit Suisse AG, erwirbt gleichzeitig sämtliche betrieblichen Immobilien der Klinik. Diese werden von der Betriebsgesellschaft im Rahmen eines langjährigen Mietvertrages zurückgemietet. Mit diesem Schritt kann das Kloster Heiligkreuz in Cham nach über 100-jähriger Besitzerschaft eine optimale Nachfolgeregelung realisieren.
Der kneipp-hof im Kanton Thurgau ist eine führende orthopädische Rehabilitationsklinik mit über 150 Zimmern sowie einem breiten ambulanten Leistungsspektrum. Der Schwerpunkt liegt in der muskuloskelettalen/orthopädischen Rehabilitation.
„Mit dem kneipp-hof erwerben wir eine ausgesprochen moderne Rehaklinik mit hervorragender medizinischer Reputation. Wir werden den bisher sehr erfolgreichen Kurs der Klinik zusammen mit der Klinikgeschäftsleitung weiterführen und unsere umfassende internationale Kompetenz in der Rehabilitation einbringen“, sagt Dr. Ernst Wastler, Vorsitzender des Vorstandes der VAMED AG.
Der kneipp-hof wurde in den vergangenen Jahren mit grossen Investitionen laufend modernisiert. Erst im Mai 2014 wurde ein neues Therapiebad in Betrieb genommen, das höchste therapeutische Ansprüche erfüllt. Sämtlichen Kunden wird ein zeitgemässes gesundheitsgerechtes Hotelambiente mit Einzelzimmer geboten. Der kneipp-hof wird auf den Spitallisten der Kantone Thurgau, Zürich, Schaffhausen und Appenzell Ausserrhoden geführt und operiert nahe an der Vollauslastung. Darüber hinaus verfügt die Klinik über ein ausgeprägtes standardisiertes Prozessmanagement und ist eine nach den international anerkannten Standards der European Foundation for Quality Management (EFQM) zertifizierte Rehabilitationsklinik.
Die VAMED wurde im Jahr 1982 gegründet und hat sich seither zum weltweit führenden Gesamtanbieter für Krankenhäuser und andere Einrichtungen im Gesundheitswesen entwickelt. In 72 Ländern auf vier Kontinenten hat der Konzern bereits mehr als 650 Projekte realisiert. Die VAMED deckt mit ihrem Angebot sämtliche Bereiche der gesundheitlichen Versorgung von Prävention/Wellness über die Akutversorgung bis zur Rehabilitation/Pflege ab. Im Jahr 2013 war die VAMED Gruppe weltweit für rund 16.000 Mitarbeiter und ein Geschäftsvolumen von 1,4 Mia. Euro verantwortlich.
Das ZETRA Team hat die Verkäufer bei dieser Transaktion als exklusiver M&A Berater begleitet.